Medifast Q3 Loss Widens, Sees Profit In Q4, Loss In FY26; Shares Up
Medifast (MED) reported a wider Q3 loss of $17.51M, or $1.57 per share, due to restructuring and lower revenue. Q4 is expected to be profitable, but FY26 will see a loss. Revenue fell 19.4% to $72.05M. Shares rose 5.51% to $12.52.
How this was made
The 30-second read
Why it matters
The earnings release provides fresh data on profitability and guidance, shifting market sentiment and prompting a pre‑market rally.
Market read
First‑report earnings and guidance move for Medifast, a small‑cap U.S. stock, driving immediate price action.
What to watch
Continued decline in active earning coaches could pressure future revenue growth despite short‑term guidance.
Background
Medifast, a metabolic and wellness company, posted Q3 results with widened losses and lower revenue, but announced Q4 profit guidance and FY26 loss expectations.
Ticker impact
Medifast reported Q3 loss widening but issued Q4 profit guidance and FY26 loss outlook, causing a 5.5% pre‑market share rise.
upward pressure from guidance lift
Guidance shift to profit in Q4 and narrowed loss range is a fresh catalyst, already moving the stock higher.
Market effects
Weight‑loss and wellness sector may see renewed investor interest as Medifast signals a turnaround.
U.S. small‑cap health‑and‑wellness stocks could experience modest buying pressure.
Limited to U.S. equity markets; no broader macro impact.
Counterpoint
The loss outlook for FY26 remains sizable; the profit guidance may be overly optimistic given declining coach numbers.
Key entities
- ExecutiveNick Johnson
CEO of Medifast who commented on revenue guidance and coach productivity.
